Clin J Am Soc Nephrol. 2020 Jul 10 doi: 10.2215/CJN.06400420.
Authors:
Angeletti A, Drovandi S, Sanguineri F, Santaniello M, Ferrando G, Forno R, Cipresso G, Caridi G,
Riella LV, Cravedi P, Ghiggeri GM
Abstract
Children seem to have a lower incidence and milder clinical course of coronavirus disease 2019 (COVID-19) (1), but data regarding disease susceptibility in specific categories of pediatric patients on chronic immunosuppression are limited (2). Decisions to reduce immunosuppression or delay redosing of B cell–depleting therapy are currently being considered as the spread of this pandemic advances and the effect of COVID-19 is feared by patients who are immunosuppressed and their physicians. This article reports the outcomes of a cohort of 159 pediatric patients (127 children [#18 years] and 32 young adults [19–28 years]) on chronic immunosuppression due to multirelapsing nephrotic syndrome on therapy with anti-CD20 antibodies living in a area in Italy with a high incidence of SARS-CoV2, including family contacts that became infected.
Link to article
